IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Title: Journal of Clinical Oncology

Abbreviated Title: JCO

Publisher: American Society of Clinical Oncology (ASCO)

ISSN (Print): 0732-183X

ISSN (Electronic): 1527-7755

Publication date Created: May 20 2019

Publication date (Print): May 20 2019

Volume: 37

Issue: 15_suppl

Page: 1003

Affiliations

[1 ]Barts Cancer Institute, Queen Mary University of London, London, United Kingdom;

[2 ]New York University Cancer Institute, New York, NY;

[3 ]University of California San Francisco Comprehensive Cancer Center, San Francisco, CA;

[4 ]National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany;

[5 ]PUCRS School of Medicine, Porto Alegre, Brazil;

[6 ]Aichi Cancer Center Hospital, Nagoya, Japan;

[7 ]Centre Eugène Marquis, Rennes, France;

[8 ]F. Hoffmann-La Roche, Ltd., Basel, Switzerland;

[9 ]Genentech, Inc., South San Francisco, CA;

[10 ]F. Hoffmann-La Roche, Ltd., Basel, CA, Switzerland;

[11 ]Dana-Farber Cancer Institute, Boston, MA;

[12 ]Peter MacCallum Cancer Centre, Melbourne, Australia;

[13 ]University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA;

Article

DOI: 10.1200/JCO.2019.37.15_suppl.1003

SO-VID: d3019572-8fa7-416d-a9ee-51159c47e896

History

Data availability:

Comments

Comment on this article

scite_

Cited by 31

See all cited by